Loading...
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
INTRODUCTION: Darbepoetin alfa (NESP(®) and ARANESP(®)) has a sustained erythropoietic activity with a longer half-life than conventional recombinant human erythropoietin. CKD-11101 is under clinical development as a biosimilar of darbepoetin alfa. The purpose of this study was to compare the pharma...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089108/ https://ncbi.nlm.nih.gov/pubmed/33953543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S303772 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|